Creo Medical Group PLC Speedboat(TM) Inject selected by NICE for assessment (2251B)
June 01 2023 - 1:00AM
UK Regulatory
TIDMCREO
RNS Number : 2251B
Creo Medical Group PLC
01 June 2023
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Speedboat (TM) Inject selected by NICE for assessment
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces that
the National Institute for Health and Care Excellence ("NICE") has
selected Speedboat Inject to be scoped and routed for guidance in
respect of the endoscopic submucosal dissection ("ESD") of lower
gastrointestinal ("GI") lesions.
This selection follows a committee review of headline data and
initiates a multi-step process whereby Speedboat's lower GI ESD
clinical and economic evidence, along with other data, is evaluated
by NICE and, if appropriate, may result in a specific NICE output
such as Medical Technologies Guidance.
NICE selected Speedboat Inject for scoping and routing because
it "anticipate[s] the topic will be of importance to patients,
carers, professionals, commissioners and the health of the public
to ensure clinical benefit is realised, inequalities in use
addressed, and help them make the best use of NHS resources".
More information on Speedboat's guidance development can be
found here .
Craig Gulliford, CEO of Creo Medical, said: "We are delighted
that Speedboat Inject has reached this stage with NICE and the
validation this provides given the progress we are already making
in the UK. We look forward to the outcome of the final stages of
the review process as NICE concludes its work."
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint
Broker)
Freddie Barnfield / Duncan Monteith
/ Euan Brown +44 (0)20 7260 1000
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFZGFKKMKGFZM
(END) Dow Jones Newswires
June 01, 2023 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024